Comment

AusBiotech and Medicines Australia have marked the two-year conclusion of the joint venture Cell and Gene Catalyst by celebrating its outcomes and committing to greater industry collaboration to unify the industry’s efforts and voice.

Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA) has completed the acquisition of the galidesivir antiviral program from NASDAQ-listed BioCryst Pharmaceuticals.

NeuroScientific Biopharmaceuticals (ASX:NSB) has announced that it has commenced the transfer of its patented manufacturing process for its mesenchymal stromal cells from Cell and Tissue Therapy (Royal Perth Hospital) to Q-Gen Cell Therapeutics of QIMR Berghofer Medical Research Institute.

A world-first Australian study is using DNA to identify a person’s genetic risk of developing multiple sclerosis to understand how their immune system responds to a common virus linked to the disease.

Amplia Therapeutics (ASX:ATX) has received Australian ethics approval for the Phase 2 clinical trial of narmafotinib in combination with the chemotherapy FOLFIRINOX.

Syntara Limited (ASX:SNT), a clinical-stage drug development company, has announced that the first participant has been dosed in the Phase 1a/b clinical trial for its topical pan-lysyl oxidase inhibitor SNT-9465, developed for the treatment of hypertrophic scars.

Prescient CEO James McDonnell said, “On behalf of the Board, I thank Prescient shareholders for their strong support of the SPP which allows us to accelerate the PTX-100 Phase 2 clinical plan. This is a pivotal moment for the business on its path towards our commercialisation objectives, and I am genuinely excited about the near-term milestones on this journey."

Alterity Therapeutics (ASX:ATH) has announced positive topline data from the ATH434-202 open-label Phase 2 clinical trial in people with multiple system atrophy.

Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the successful completion of a $203 million placement to institutional investors.

Radiopharm Theranostics (ASX: RAD) has announced that the US FDA has granted clearance of its Investigational New Drug application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody.

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at $439 million.

Sanofi has agreed to acquire Vicebio, a privately held biotechnology company headquartered in London, which has rights to the Molecular Clamp Technology developed at the University of Queensland.